ReviewWorld journal of gastroenterology2018
Gastrointestinal stromal tumors: A multidisciplinary challenge.
Review in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 83 citations in OpenAlex.
- Precision oncology meets Generative AI: assessing large language models in multidisciplinary GIST tumor boards.BMC cancer · 2026Article
- Metabolic profile alterations as early indicators of gastrointestinal stromal tumors (GISTs) recurrence and imatinib resistance.Journal of gastrointestinal oncology · 2026Article
- Prediction Model of Malignant Risk of Gastrointestinal Stromal Tumor Based on Endoscopic Ultrasonography.Digestive diseases (Basel, Switzerland) · 2026Article
- Ulcerated benign jejunal gastrointestinal stromal tumor causing gastrointestinal bleeding: A case report.World journal of clinical cases · 2025Article
- Ultrasound elastography for the differential diagnosis of benign and malignant gastrointestinal stromal tumors.World journal of gastrointestinal surgery · 2025Article
- A machine learning model integrating clinical-radiomics-deep learning features accurately predicts postoperative recurrence and metastasis of primary gastrointestinal stromal tumors.Insights into imaging · 2025Article
- Review
- Multiple Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumors of the Stomach: A Case Report.The American journal of case reports · 2025Article
- A Lightweight Machine Learning Model for High Precision Gastrointestinal Stromal Tumors Identification.Bioengineering (Basel, Switzerland) · 2025Article
- The role of ultrasound in assessment and prediction of the efficacy of preoperative targeted therapy for gastrointestinal mesenchymal tumors compared with pathology.Journal of medical ultrasonics (2001) · 2025Article
- Rapidly Growing Gastrointestinal Stromal Tumor on the Esophagus.The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
- Advancement in medical treatment for gastrointestinal stromal tumors (GISTs): a ray of hope.Annals of medicine and surgery (2012) · 2025Review
- Article
- Article
- Gastrointestinal Stromal Tumor (GIST) Masquerading as a Pancreatic Pseudocyst: A Rare Case Report.Cureus · 2024Article
- Article
- Clinical characteristics and prognostic analysis of postoperative recurrence or metastasis of low-risk gastrointestinal stromal tumors.World journal of surgical oncology · 2024Article
- Article
- A gist on an obscure neoplasm in Ghana: gastrointestinal stromal tumours.BMC research notes · 2023Article
- A Rare Case of a Rectal Gastrointestinal Stromal Tumor (GIST) Discovered During a Routine Colonoscopy.Cureus · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors located in the alimentary tract. Its usual manifestation is gastrointestinal bleeding. However, small asymptomatic lesions are frequently detected as incidental finding. Characteristically, most GISTs (> 95%) are positive for the KIT protein (CD117) by IHC staining and approximately 80%-90% of GISTs carry a mutation in the c-KIT or PDGFRA genes. Mutational analysis should be performed when planning adjuvant and neoadjuvant therapy, due to its possible resistance to conventional treatment. The arise of tyrosine kinase inhibitor has supposed a revolution in GISTs treatment being useful as adjuvant, neoadjuvant or recurrence disease treatment. That is why a multidisciplinary approach to this disease is required. The correct characterization of the tumor at diagnosis (the diagnosis of recurrences and the evaluation of the response to treatment with tyrosine kinase inhibitors) is fundamental for facing these tumors and requires specialized Endoscopist, Radiologists and Nuclear Medicine Physician. Surgery is the only potentially curative treatment for suspected resectable GIST. In the case of high risk GISTs, surgery plus adjuvant Imatinib-Mesylate for 3 years is the standard treatment. Neoadjuvant imatinib-mesylate should be considered to shrink the tumor in case of locally advanced primary or recurrence disease, unresectable or potentially resectable metastasic tumors, and potentially resectable disease in complex anatomic locations to decrease the related morbidity. In the case of Metastatic GIST under Neoadjuvant treatment, when there are complete response, stable disease or limited disease progression, complete cytoreductive surgery could be a therapeutic option if feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.